References
Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628
Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525
Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi:10.1016/j.juro.2016.12.003 (Epub ahead of print)
Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46
O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251
Author contributions
PBØ: Project development, Data management, Data analysis, Manuscript editing. TWK: Data management, Data analysis, Manuscript editing. MF: Project development, Data management, Data analysis, Manuscript writing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
This is a letter to the editor not directly involving human participants or animals. The authors would like to declare the following conflicts of interest: Peter B. Østergren has received honorarium as a speaker for Astellas and Ferring. Mikkel Fode has received honorarium as a speaker and advisory board member for Astellas. Tobias Wirenfeldt Klausen has no conflicts of interest.
Additional information
This comment refers to the article available at doi:10.1007/s00345-016-1831-5.
Rights and permissions
About this article
Cite this article
Østergren, P.B., Klausen, T.W. & Fode, M. No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer. World J Urol 36, 681–682 (2018). https://doi.org/10.1007/s00345-017-2012-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-017-2012-x